Surrobodies™ are the result of Sea Lane’s engineering of the pre-B cell receptor. Our objective in inventing the therapeutic Surrobody was to create a new entity with long half-life and true effector functions that facilitates and simplifies next generation technologies like bi-specificity and drug conjugation. Our robust Surrobody library is the equivalent in complexity and design of our world class synthetic antibody library.
Click Here to see the design and characteristics of Surrobodies.
Click Here to see our "Combinatorial surrobody libraries" article published in the Proceedings of the National Academy of Sciences
Click Here to see our "Surrobodies With Functional Tails" article published in the Journal of Molecular Biology
Sea Lane is actively employing the Surrobody technology in the discovery and research stages of creating an oncology and metabolic disease pipeline. With the guidance of our world-class advisors, we are pursuing programs based on Surrobody functional attributes directed at validated and high value targets. This allows us to reduce the risk of the programs while capitalizing on the distinguishing features of Surrobodies. Sea Lane is open to discussing our approach in these and other disease areas.